Payoneer to Report First Quarter 2025 Results on May 7, 2025

Payoneer to Report First Quarter 2025 Results on May 7, 2025

NEW YORK–(BUSINESS WIRE)–
Payoneer (NASDAQ: PAYO), the financial technology company empowering the world’s small and medium-sized businesses (SMBs) to transact, do business, and grow globally, will report its First Quarter 2025 financial results on Wednesday, May 7, 2025, before the market opens. Senior management will also host a conference call and earnings webcast to discuss financial results at 8:30 a.m. Eastern Time the same day. A live webcast and replay of the event will be available on the Payoneer Investor Relations website at https://investor.payoneer.com.

About Payoneer

Payoneer is the financial technology company empowering the world’s small and medium-sized businesses to transact, do business, and grow globally. Payoneer was founded in 2005 with the belief that talent is equally distributed, but opportunity is not. It is our mission to enable any entrepreneur and business anywhere to participate and succeed in an increasingly digital global economy. Since our founding, we have built a global financial stack that removes barriers and simplifies cross-border commerce. We make it easier for millions of SMBs, particularly in emerging markets, to connect to the global economy, pay and get paid, manage their funds across multiple currencies, and grow their businesses.

Investor Contact:

Michelle Wang

[email protected]

Media Contact:

Angela Sullivan

[email protected]

KEYWORDS: United States North America New York

INDUSTRY KEYWORDS: Professional Services Payments Small Business Technology Finance Electronic Commerce Fintech

MEDIA:

Logo
Logo

Roku Reinforces Commitment to Streaming Leadership

Roku Reinforces Commitment to Streaming Leadership

New TVs, streaming and smart home devices, and software features open the next chapter of the Roku Experience

SAN JOSE, Calif.–(BUSINESS WIRE)–
Today, Roku, Inc. (NASDAQ: ROKU), the #1 TV streaming platform in the U.S., Canada, and Mexico*, unveiled a powerful new device lineup and software updates designed for streamers. Every day, the Roku Experience enhances television viewing for over 90 million households worldwide, including more than half of all broadband homes in the U.S. With a growing global footprint, Roku continues to lead the way in delivering innovative devices that make TV delightfully simple, enjoyable, and better for everyone.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250423832942/en/

Today, Roku unveiled a powerful new device lineup and software updates designed for streamers.

Today, Roku unveiled a powerful new device lineup and software updates designed for streamers.

“As we step into the new streaming-first era, our focus at Roku is where it’s been since day one: redefining what streaming can be,” said Anthony Wood, CEO and Founder at Roku. “With our intuitive interface, unmatched scale and insights, and cutting-edge innovation, the full Roku Experience doesn’t just meet expectations—it sets a new standard. I’m proud of how far we’ve come, and I’m even more excited about where we’re headed next.”

“Our mission remains the same—to deliver better TV for everyone,” said Mustafa Ozgen, President of Devices, Product & Technology at Roku. “With this new device lineup and beyond, we are changing the future of television, with streaming that is seamless, innovative, and enjoyable.”

Read on to learn more about Roku’s latest updates.

Latest product and platform enhancements

  • The Roku Experience keeps getting better: New features across Roku’s intuitive platform make streaming smoother and more personalized. New content discovery updates include a “Coming Soon to Theaters” row, personalized sports highlights, and more. Learn more here.
  • Meet Roku’s new streaming players: Roku is introducing two new streaming players, the Roku Streaming Stick and Roku Streaming Stick Plus. These new devices are the most compact sticks on the market—over 35% smaller than other brands—all without compromising performance or speed. Learn more here.
  • Meet our new Roku-made TVs: Roku is bringing unique hardware innovations and under-the-hood enhancements across Roku-made TVs, delivering great TV for everyone. Learn more here.
  • Deeper connectivity in the home: Roku Smart Home products, along with Roku’s purpose-built Smart Home OS, are designed to make your home smarter and safer. With no plugs required and impressive battery life, the new Roku Battery Camera and Roku Battery Camera Plus are perfect for any outdoor or indoor space. Learn more here.
  • Roku TV program expands to projectors: Roku announced an all-new Roku TV Smart Projector reference design, available to all Roku TV partners. More details coming soon.

Roku global highlights

  • New Roku Players come to Canada: We are expanding the Roku player lineup to Canadians with the launch of the Roku Streaming Stick and Roku Streaming Stick Plus. Learn more here.
  • New Roku Players and Sports Zone to launch in Mexico: In the coming weeks, the Sports Zone will launch in Mexico, delivering a one-stop hub to catch all your go-to games. In addition, the Roku player lineup will feature two new models: Roku Streaming Stick and Roku Streaming Stick Plus. Learn more here.
  • New Roku Players coming to the United Kingdom: We are updating the Roku player lineup in the U.K., with the launch of the Roku Streaming Stick and Roku Streaming Stick Plus. Learn more here.
  • Roku Players lineup expanding in Central and South America: The Roku player family will be updated with the addition of Roku Streaming Stick and Roku Streaming Stick Plus in Argentina, Chile, Colombia, Peru, Costa Rica, El Salvador, Honduras, Guatemala, Nicaragua, and Panama.
  • New Roku Players in Brazil: We are excited to introduce the Roku Streaming Stick and the Roku Streaming Stick Plusin Brazil. The new players come with upgraded features and offer an even better streaming experience. Learn more here.

For more information on Roku’s new lineup of televisions, players, and smart home products, plus its content, ads, and advanced operating system, please visit Roku.com.

*By hours streamed (Hypothesis Group: Dec 2024)

About Roku, Inc.

Roku pioneered streaming on TV. We connect users to the content they love, enable content publishers to build and monetize large audiences, and provide advertisers with unique capabilities to engage consumers. Roku TV™ models, Roku streaming players, and TV- related audio devices are available in various countries around the world through direct retail sales and/or licensing arrangements with TV OEM brands. Roku Smart Home products are sold exclusively in the United States. Roku also operates The Roku Channel, the home of free and premium entertainment with exclusive access to Roku Originals. The Roku Channel is available in the United States, Canada, Mexico, and the United Kingdom. Roku is headquartered in San Jose, Calif., U.S.A.

This press release contains “forward-looking” statements that are based on our beliefs and assumptions and on information currently available to us on the date of this press release. Forward-looking statements may involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance, or achievements to be materially different from those expressed or implied by the forward-looking statements. These statements include but are not limited to those related to Roku’s TV streaming product lineup, including the features, functionality, and timing and location of product availability; trends in TV streaming; and the benefits of the Roku Experience and platform. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in the forward-looking statements, even if new information becomes available in the future. Important factors that could cause our actual results to differ materially are detailed from time to time in the reports we file with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K. Copies of reports filed with the SEC are posted on Roku’s websites and are available from Roku without charge.

ROKU, STREAMING STICK, and ROKU TV are trademarks or registered trademarks of Roku, Inc., in the United States and other jurisdictions.

Media Contact

Sarah Novatt

[email protected]

KEYWORDS: United States California

INDUSTRY KEYWORDS: Software Photography Hardware TV and Radio General Entertainment Technology Other Technology Entertainment

MEDIA:

Photo
Photo
Today, Roku unveiled a powerful new device lineup and software updates designed for streamers.
Logo
Logo

Merus Announces Abstract Accepted for Presentation at the 2025 ASCO® Annual Meeting

– Petosemtamab in combination with pembrolizumab in 1L PD-L1+ r/m HNSCC interim clinical data selected for poster presentation

– Conference call on Thursday, May 22 at 5:30 p.m. ET to discuss full ASCO® data set

UTRECHT, The Netherlands and CAMBRIDGE, Mass., April 23, 2025 (GLOBE NEWSWIRE) — Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), an oncology company developing innovative, full-length multispecific antibodies and antibody drug conjugates (Biclonics®, Triclonics® and ADClonics®), today announced the acceptance of an abstract for presentation at the 2025 American Society of Clinical Oncology® (ASCO®) Annual Meeting, being held in Chicago, Illinois on May 30- June 3, 2025.

An updated analysis of the interim clinical data from the phase 2 trial of petosemtamab with pembrolizumab as 1L treatment of PD-L1+ recurrent/metastatic (r/m) head and neck squamous cell carcinoma (HNSCC) will be presented in a poster at 2025 ASCO®. The presentation will include data on the entire 45 patient dataset and follows the early clinical efficacy and encouraging safety data previously presented at 2024 ASCO®.

“We continue to believe that petosemtamab has the potential to be a first and best-in-class, practice-changing medicine for the treatment of r/m HNSCC. While the decision to have a poster presentation at 2025 ASCO® was based on the limited data included in the submitted abstract, we are very much looking forward to sharing the robust updated interim phase 2 data, on the entire 45 patient data set, on the upcoming investor conference call and in our presentation at the conference,” said Bill Lundberg, M.D., President, Chief Executive Officer of Merus. “We believe petosemtamab continues to demonstrate substantial clinical activity superior to historical controls, based on the magnitude and consistency of efficacy, not just on one endpoint, but across ORR, PFS and OS in the overall population and within important subgroups of HPV disease and PD-L1 expression levels. On the back of these data, and the strong execution of our phase 3 trials, we believe petosemtamab has the potential to become a new standard of care for r/m HNSCC.”

Poster presentation:

Title: Petosemtamab (MCLA-158) with pembrolizumab as first-line (1L) treatment of PD-L1+ recurrent/metastatic (r/m) head and neck squamous cell carcinoma (HNSCC): Phase 2 trial  
Abstract #: 6024
Poster Board: 432
Session Title: Head and Neck Cancer
Session Date and Time: June 2, 2025, 9:00-12:00 CT

The abstracts will be available on the ASCO® website on May 22, 2025 at 5:00 p.m. ET. The full presentation will be available on the Merus website at the start of the session.

Company Conference Call and Webcast Information

Merus will hold a conference call and webcast for investors on Thursday, May 22, 2025 at 5:30 p.m. ET. A replay will be available after the completion of the call in the Investors and Media section of our website for a limited time. 
Date & Time: May 22, 2025 at 5:30 p.m. ET
Webcast link: Available on our website
Dial-in: Toll Free: (800) 715-9871 / International: (646) 307-1963
Conference ID: 7517301 or Merus NV call

About Petosemtamab

Petosemtamab, or MCLA-158, is a Biclonics® low-fucose human full-length IgG1 antibody targeting the epidermal growth factor receptor (EGFR) and the leucine-rich repeat containing G-protein-coupled receptor 5 (LGR5). Petosemtamab is designed to exhibit three independent mechanisms of action including inhibition of EGFR-dependent signaling, LGR5 binding leading to EGFR internalization and degradation in cancer cells, and enhanced antibody-dependent cell-mediated cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP) activity.

About Head and Neck Cancer

Head and neck squamous cell carcinoma (HNSCC) describes a group of cancers that develop in the squamous cells that line the mucosal surfaces of the mouth, throat, and larynx. These cancers begin when healthy cells change and grow in an unchecked manner, ultimately forming tumors. HNSCC is generally associated with tobacco consumption, alcohol use and/or HPV infections, depending on where they develop geographically. HNSCC is the sixth most common cancer worldwide and it is estimated that there were more than 930,000 new cases and over 465,000 deaths from HNSCC globally in 2020.1 The incidence of HNSCC continues to rise and is anticipated to increase by 30% to more than 1 million new cases annually by 2030.2 HNSCC is a serious and life-threatening disease with poor prognosis despite currently available standard of care therapies.




Sung et al. CA Cancer J Clin, 71:209-49, 2021; 



Johnson, D.E., Burtness, B., Leemans, C.R. et al. Head and neck squamous cell carcinoma. Nat Rev Dis Primers 6(1):92, 2020

About LiGeR-HN1

LiGeR-HN1, a phase 3 trial, will evaluate the safety and efficacy of petosemtamab in combination with pembrolizumab, compared to pembrolizumab in 1L PD-L1+ r/m HNSCC patients. The trial is open to adult patients eligible to receive pembrolizumab as 1L monotherapy with tumors expressing PD-L1, CPS ≥1. The primary endpoints are overall response rate as assessed by BICR based on RECIST v1.1 and overall survival. Secondary endpoints are duration of response and progression free survival. Merus plans to enroll approximately 500 patients in the trial.

About Merus N.V.

Merus is an oncology company developing innovative full-length human bispecific and trispecific antibody therapeutics, referred to as Multiclonics®. Multiclonics® are manufactured using industry standard processes and have been observed in preclinical and clinical studies to have several of the same features of conventional human monoclonal antibodies, such as long half-life and low immunogenicity. For additional information, please visit Merus’ website and LinkedIn.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation, statements regarding the clinical development of our clinical candidates, including petosemtamab, future clinical trial results or interim data, clinical activity and safety profile, and development plans in the on-going trials and described in forthcoming posters or presentations; our belief that petosemtamab has the potential to be a first and best-in-class, practice-changing medicine for the treatment of r/m HNSCC; our sharing the robust updated interim phase 2 data, on the entire 45 patient data set, on the upcoming investor conference call and in our presentation at the conference; our belief that petosemtamab continues to demonstrate substantial clinical activity superior to historical controls, based on the magnitude and consistency of efficacy, not just on one endpoint, but across ORR, PFS and OS in the overall population and within important subgroups of HPV disease and PD-L1 expression levels; our execution of our phase 3 trials; and our belief that petosemtamab has the potential to become a new standard of care for r/m HNSCC. These forward-looking statements are based on management’s current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: our need for additional funding, which may not be available and which may require us to restrict our operations or require us to relinquish rights to our technologies or antibody candidates; potential delays in regulatory approval, which would impact our ability to commercialize our product candidates and affect our ability to generate revenue; the lengthy and expensive process of clinical drug development, which has an uncertain outcome; the unpredictable nature of our early stage development efforts for marketable drugs; potential delays in enrollment of patients, which could affect the receipt of necessary regulatory approvals; our reliance on third parties to conduct our clinical trials and the potential for those third parties to not perform satisfactorily; impacts of the volatility in the global economy, including global instability, including the ongoing conflicts in Europe and the Middle East; we may not identify suitable Biclonics® or bispecific antibody candidates under our collaborations or our collaborators may fail to perform adequately under our collaborations; our reliance on third parties to manufacture our product candidates, which may delay, prevent or impair our development and commercialization efforts; protection of our proprietary technology; our patents may be found invalid, unenforceable, circumvented by competitors and our patent applications may be found not to comply with the rules and regulations of patentability; we may fail to prevail in potential lawsuits for infringement of third-party intellectual property; and our registered or unregistered trademarks or trade names may be challenged, infringed, circumvented or declared generic or determined to be infringing on other marks.

These and other important factors discussed under the caption “Risk Factors” in our Annual Report on Form 10-K for the period ended December 31, 2024, filed with the Securities and Exchange Commission, or SEC, on February 27, 2025, and our other reports filed with the SEC, could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management’s estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change, except as required under applicable law. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.

Multiclonics®, Biclonics® and Triclonics® are registered trademarks of Merus N.V.



Investor and Media Inquiries:

Sherri Spear
Merus N.V.
SVP Investor Relations and Strategic Communications
617-821-3246
[email protected]

Kathleen Farren
Merus N.V.
Director Investor Relations and Corporate Communications
617-230-4165
[email protected]

UMC Reports First Quarter 2025 Results

UMC Reports First Quarter 2025 Results

22nm revenue surges 46% QoQ on display driver and networking chip demand

Inauguration of new Singapore fab to support future 22nm growth

First Quarter 2025 Overview1:

  • Revenue: NT$57.86 billion (US$1.74 billion)
  • Gross margin: 26.7%; Operating margin: 16.9%
  • Revenue from 22/28nm: 37%
  • Capacity utilization rate: 69%
  • Net income attributable to shareholders of the parent: NT$7.78 billion (US$234 million)
  • Earnings per share: NT$0.62; earnings per ADS: US$0.093

TAIPEI, Taiwan–(BUSINESS WIRE)–United Microelectronics Corporation (NYSE: UMC; TWSE: 2303) (“UMC” or “The Company”), a leading global semiconductor foundry, today announced its consolidated operating results for the first quarter of 2025.

First quarter consolidated revenue was NT$57.86 billion, decreasing 4.2% from NT$60.39 billion in 4Q24. Compared to a year ago, 1Q25 revenue increased 5.9%. Consolidated gross margin for 1Q25 was 26.7%. Net income attributable to the shareholders of the parent was NT$7.78 billion, with earnings per ordinary share of NT$0.62.

Jason Wang, co-president of UMC, said, “Our results in the first quarter were in line with previous guidance, with flattish wafer shipments and the one-time pricing adjustment at the beginning of the year to reflect market conditions. First-quarter highlights include 22/28nm revenue hitting a record high, representing 37% of total sales. That was driven by a 46% quarter-over-quarter increase in 22nm revenue from products such as OLED display driver ICs, image signal processors as well as digital TV, WiFi and audio codec chips. We expect customers to tape-out additional 22nm products in the coming quarters as customers increasingly migrate to our 22nm logic and specialty platforms for next-generation applications. Earlier this month, we also officially inaugurated our new Singapore Phase 3 fab, which will provide additional 22nm capacity to support future growth. Pilot runs are underway and is on schedule to ramp up to volume production early 2026. The expansion in Singapore also further broadens our geographic diversification, enabling customers to strengthen their supply chain resilience. In February, our Board of Directors proposed a cash dividend of NT$2.85 per share, which is subject to approval from shareholders in the upcoming annual general meeting.”

Co-president Wang added, “Looking ahead to the second quarter, we are expecting a moderate rebound in demand across all segments according to near-term alignment with customers. Beyond that, we are cautious about wafer demand projections as policies and markets are still adjusting to the recent tariff announcements. To navigate this challenging environment, we are working closely with customers to monitor trends in end market demand. We are also strengthening our competitive advantages by focusing on execution of key technology projects, such as the 12nm collaboration with U.S. partner, and ensuring our customers have access to geographically diverse manufacturing options. In addition, we are implementing cost reduction plans and accelerating AI and intelligent manufacturing systems to enhance operational efficiency. Through these key focuses, we are confident that UMC can maintain our financial and business resilience.”

Co-president Wang said, “In the first quarter, UMC was honored to receive high ratings in two key sustainability benchmarks. In the Sustainability Yearbook 2025 published by S&P Global, UMC is the only semiconductor company globally to earn the ‘Top 1%’ ranking based on the company’s Corporate Sustainability Assessment (CSA) score. UMC also stood out in the CDP’s annual assessment as the sole semiconductor company to be awarded the highest ‘A’ rating in both Climate Change and Water Security categories.”

Summary of Operating Results

Operating Results

(Amount: NT$ million)

1Q25

4Q24

QoQ %

change

1Q24

YoY %

change

Operating Revenues

57,859

 

60,386

 

(4.2

)

54,632

 

5.9

 

Gross Profit

15,447

 

18,343

 

(15.8

)

16,899

 

(8.6

)

Operating Expenses

(6,123

)

(6,748

)

(9.3

)

(5,747

)

6.5

 

Net Other Operating Income and Expenses

462

 

362

 

27.6

 

513

 

(9.9

)

Operating Income

9,786

 

11,957

 

(18.2

)

11,665

 

(16.1

)

Net Non-Operating Income and Expenses

(439

)

(1,443

)

(69.5

)

1,056

 

 

Net Income Attributable to Shareholders of the Parent

7,777

 

8,497

 

(8.5

)

10,456

 

(25.6

)

EPS (NT$ per share)

0.62

 

0.68

 

 

0.84

 

 

EPS (US$ per ADS)

0.093

 

0.104

 

 

0.131

 

 

Exchange rate (USD/NTD)

33.18

 

32.78

 

 

31.99

 

 

Note:Sums may not equal totals due to rounding.

First quarter operating revenues declined 4.2% sequentially to NT$57.86 billion. Revenue contribution from 40nm and below technologies represented 53% of wafer revenue. Gross profit decreased 15.8% QoQ to NT$15.45 billion, or 26.7% of revenue. Operating expenses decreased 9.3% to NT$6.12 billion. Net other operating income increased 27.6% to NT$0.46 billion. Net non-operating expenses totaled NT$0.44 billion. Net income attributable to shareholders of the parent amounted to NT$7.78 billion.

Earnings per ordinary share for the quarter was NT$0.62. Earnings per ADS was US$0.093. The basic weighted average number of shares outstanding in 1Q25 was 12,484,780,989, compared with 12,481,192,676 shares in 4Q24 and 12,414,087,724 shares in 1Q24. The diluted weighted average number of shares outstanding was 12,579,207,466 in 1Q25, compared with 12,610,756,874 shares in 4Q24 and 12,577,525,057 shares in 1Q24. The fully diluted shares counted on March 31, 2025 were approximately 12,579,207,000.

Detailed Financials Section

Operating revenues decreased to NT$57.86 billion. COGS grew 0.9% to NT$42.41 billion, which included a 4.1% sequential increase in depreciation. Gross profit decreased 15.8% QoQ to NT$15.45 billion. Operating expenses decreased to NT$6.12 billion, as G&A declined 13.9% QoQ to NT$1.54 billion, R&D declined 8.5% to NT$3.96 billion, and Sales & Marketing also declined 0.7% to NT$0.62 billion. Net other operating income was NT$0.46 billion. In 1Q25, operating income declined 18.2% QoQ to NT$9.79 billion.

COGS & Expenses

(Amount: NT$ million)

1Q25

4Q24

QoQ %

change

1Q24

YoY %

change

Operating Revenues

57,859

 

60,386

 

(4.2

)

54,632

 

5.9

 

COGS

(42,412

)

(42,043

)

0.9

 

(37,733

)

12.4

 

Depreciation

(12,321

)

(11,841

)

4.1

 

(9,335

)

32.0

 

Other Mfg. Costs

(30,091

)

(30,202

)

(0.4

)

(28,398

)

6.0

 

Gross Profit

15,447

 

18,343

 

(15.8

)

16,899

 

(8.6

)

Gross Margin (%)

26.7

%

30.4

%

 

30.9

%

 

Operating Expenses

(6,123

)

(6,748

)

(9.3

)

(5,747

)

6.5

 

Sales & Marketing

(619

)

(623

)

(0.7

)

(684

)

(9.5

)

G&A

(1,542

)

(1,791

)

(13.9

)

(1,702

)

(9.4

)

R&D

(3,964

)

(4,334

)

(8.5

)

(3,407

)

16.3

 

Expected Credit Impairment Gain

2

 

0

 

523.3

 

46

 

(94.7

)

Net Other Operating Income & Expenses

462

 

362

 

27.6

 

513

 

(9.9

)

Operating Income

9,786

 

11,957

 

(18.2

)

11,665

 

(16.1

)

Note:Sums may not equal totals due to rounding.

Net non-operating expenses in 1Q25 was NT$0.44 billion, primarily reflecting the NT$0.77 billion in net investment loss, offset by the NT$0.22 billion in net interest income, and the NT$0.12 billion in exchange gain.

Non-Operating Income and Expenses

(Amount: NT$ million)

1Q25

4Q24

1Q24

 

Non-Operating Income and Expenses

(439

)

(1,443

)

1,056

 

Net Interest Income and Expenses

219

 

290

 

676

 

Net Investment Gain and Loss

(769

)

(2,614

)

(324

)

Exchange Gain and Loss

115

 

877

 

697

 

Other Gain and Loss

(5

)

4

 

7

 

Note:Sums may not equal totals due to rounding.

In 1Q25, cash inflow from operating activities was NT$23.83 billion. Cash outflow from investing activities totaled NT$10.51 billion, which included NT$14.57 billion in capital expenditure, resulting in free cash flow of NT$9.26 billion. Cash outflow from financing was NT$13.78 billion, primarily from NT$13.02 billion in bank loans. Net cash flow in 1Q25 amounted to NT$1.35 billion. Over the next 12 months, the company expects to repay NT$5.62 billion in bank loans.

Cash Flow Summary

(Amount: NT$ million)

For the 3-Month Period Ended

Mar. 31, 2025

For the 3-Month Period Ended

Dec. 31, 2024

Cash Flow from Operating Activities

23,826

 

32,977

 

Net income before tax

9,347

 

10,514

 

Depreciation & Amortization

14,128

 

13,463

 

Share of loss of associates and

joint ventures

208

 

1,800

 

Income tax paid

(585

)

(137

)

Changes in working capital & others

728

 

7,337

 

Cash Flow from Investing Activities

(10,506

)

(16,968

)

Acquisition of PP&E

(14,153

)

(18,275

)

Acquisition of intangible assets

(329

)

(877

)

Others

3,976

 

2,184

 

Cash Flow from Financing Activities

(13,776

)

(14,305

)

Bank loans

(13,018

)

(10,495

)

Redemption of bonds

 

(3,400

)

Others

(758

)

(410

)

Effect of Exchange Rate

1,810

 

(111

)

Net Cash Flow

1,354

 

1,593

 

Beginning balance

105,000

 

103,407

 

Ending balance

106,354

 

105,000

 

Note:Sums may not equal totals due to rounding.

Cash and cash equivalents increased to NT$106.35 billion. Days of inventory decreased 3 days to 77 days.

Current Assets

(Amount: NT$ billion)

1Q25

4Q24

1Q24

Cash and Cash Equivalents

106.35

105.00

119.43

Accounts Receivable

34.80

33.34

30.68

Days Sales Outstanding

54

51

50

Inventories, net

35.43

35.78

34.59

Days of Inventory

77

80

85

Total Current Assets

192.32

189.68

205.16

Current liabilities decreased to NT$72.87 billion. Long-term credit/bonds decreased to NT$44.63 billion. Total liabilities decreased to NT$182.13 billion, leading to a debt to equity ratio of 47%.

Liabilities

(Amount: NT$ billion)

1Q25

4Q24

1Q24

 

Total Current Liabilities

72.87

 

75.26

 

88.40

 

Accounts Payable

9.27

 

7.63

 

7.46

 

Short-Term Credit / Bonds

17.63

 

19.51

 

25.60

 

Payables on Equipment

8.46

 

10.52

 

13.97

 

Other

37.51

 

37.60

 

41.37

 

Long-Term Credit / Bonds

44.63

 

55.53

 

43.45

 

Total Liabilities

182.13

 

192.02

 

188.85

 

Debt to Equity

47

%

51

%

50

%

Analysis of Revenue2

Revenue from Asia Pacific increased to 66%, while business from North America was 22% of sales. Business from Europe decreased to 7%, while contribution from Japan was 5%.

Revenue Breakdown by Region

Region

1Q25

4Q24

3Q24

2Q24

1Q24

North America

22

%

25

%

26

%

25

%

25

%

Asia Pacific

66

%

61

%

65

%

64

%

63

%

Europe

7

%

11

%

5

%

7

%

8

%

Japan

5

%

3

%

4

%

4

%

4

%

Revenue contribution from 22/28nm increased to 37% of wafer revenue, while 40nm contribution remained at 16% of sales.

Revenue Breakdown by Geometry

Geometry

1Q25

4Q24

3Q24

2Q24

1Q24

14nm and below

0

%

0

%

0

%

0

%

0

%

14nm<x<=28nm

37

%

34

%

35

%

33

%

33

%

28nm<x<=40nm

16

%

16

%

13

%

12

%

14

%

40nm<x<=65nm

16

%

16

%

15

%

15

%

18

%

65nm<x<=90nm

8

%

11

%

10

%

12

%

10

%

90nm<x<=0.13um

7

%

10

%

10

%

11

%

9

%

0.13um<x<=0.18um

10

%

9

%

11

%

10

%

11

%

0.18um<x<=0.35um

5

%

4

%

5

%

5

%

4

%

0.5um and above

1

%

0

%

1

%

2

%

1

%

Revenue from fabless customers accounted for 82% of revenue.

Revenue Breakdown by Customer Type

Customer Type

1Q25

4Q24

3Q24

2Q24

1Q24

Fabless

82

%

84

%

85

%

87

%

82

%

IDM

18

%

16

%

15

%

13

%

18

%

Revenue from the communication segment accounted for 40%, while business from computer applications was 11% of sales. Business from consumer applications increased to 34%, while other segments was 15% of revenue.

Revenue Breakdown by Application (1)

Application

1Q25

4Q24

3Q24

2Q24

1Q24

Computer

11

%

13

%

13

%

15

%

13

%

Communication

40

%

39

%

42

%

39

%

48

%

Consumer

34

%

29

%

31

%

31

%

23

%

Others

15

%

19

%

14

%

15

%

16

%

 

(1)Computer consists of ICs such as CPU, GPU, HDD controllers, DVD/CD-RW control ICs, PC chipset, audio codec, keyboard controller, monitor scaler, USB, I/O chipset, WLAN. Communication consists of handset components, broadband, bluetooth, Ethernet, LAN, DSP, etc. Consumer consists of ICs used for DVD players, DTV, STB, MP3/MP4, flash controller, game consoles, DSC, smart cards, toys, etc.

Blended ASP Trend

Blended average selling price (ASP) declined in 1Q25.

(To view blended ASP trend, please click here for 1Q25 ASP)

Shipment and Utilization Rate3

Wafer shipments remained flat, accounting for 910K in the first quarter, while quarterly capacity was 1,264K. Overall utilization rate in 1Q25 slightly declined to 69%.

Wafer Shipments

1Q25

4Q24

3Q24

2Q24

1Q24

Wafer Shipments

(12” K equivalents)

910

 

909

 

896

 

831

 

810

 

 

Quarterly Capacity Utilization Rate

 

1Q25

4Q24

3Q24

2Q24

1Q24

Utilization Rate

69

%

70

%

71

%

68

%

65

%

Total Capacity

(12” K equivalents)

1,264

 

1,280

 

1,274

 

1,257

 

1,212

 

Capacity4

Total capacity in the first quarter decreased to 1,264K 12-inch equivalent wafers. Capacity will grow in the second quarter of 2025 to 1,290K 12-inch equivalent wafers.

Annual Capacity in

Quarterly Capacity in

thousands of wafers

thousands of wafers

FAB

Geometry

(um)

2024

2023

2022

2021

FAB

2Q25E

1Q25

4Q24

3Q24

WTK

6″

5 – 0.15

331

 

328

 

335

 

329

 

WTK

6″

80

78

83

83

8A

8″

3 – 0.11

829

 

811

 

765

 

755

 

8A

8″

215

212

207

207

8C

8″

0.35 – 0.11

477

 

473

 

459

 

459

 

8C

8″

125

123

119

119

8D

8″

0.18 – 0.09

473

 

440

 

410

 

380

 

8D

8″

118

116

118

118

8E

8″

0.6 – 0.14

524

 

490

 

469

 

457

 

8E

8″

131

129

131

131

8F

8″

0.18 – 0.11

578

 

570

 

550

 

514

 

8F

8″

146

144

145

145

8S

8″

0.18 – 0.11

455

 

447

 

443

 

408

 

8S

8″

117

115

114

114

8N

8″

0.5 – 0.11

1,013

 

996

 

952

 

917

 

8N

8″

250

246

254

254

12A

12″

0.13 – 0.014

1,556

 

1,305

 

1,170

 

1,070

 

12A

12″

409

402

409

403

12i

12″

0.13 – 0.040

678

 

655

 

655

 

641

 

12i

12″

172

169

172

172

12X

12″

0.080 – 0.022

318

 

317

 

314

 

284

 

12X

12″

80

78

80

80

12M

12″

0.13 – 0.040

455

 

438

 

436

 

395

 

12M

12″

119

113

115

115

Total(1)

5,022

 

4,674

 

4,458

 

4,201

 

Total

1,290

1,264

1,280

1,274

YoY Growth Rate

7

%

5

%

6

%

3

%

 

 

 

 

 

 

(1) One 6-inch wafer is converted into 0.25 (62/122) 12-inch equivalent wafer; one 8-inch wafer is converted into 0.44 (82/122) 12-inch equivalent wafers. Total capacity figures are expressed in 12-inch equivalent wafers.

CAPEX

CAPEX spending in 1Q25 totaled US$443 million. 2025 cash-based CAPEX budget will be US$1.8 billion.

Capital Expenditure by Year – in US$ billion

Year

2024

2023

2022

2021

2020

CAPEX

$

2.9

$

3.0

$

2.7

$

1.8

$

1.0

 
2025 CAPEX Plan

8″

12″

Total

10%

90%

US$1.8 billion

Second Quarter 2025 Outlook & Guidance

Quarter-over-Quarter Guidance:

  • Wafer Shipments: Will increase by 5-7%
  • ASP in USD: Will remain flat
  • Gross Profit Margin: Will be approximately 30%
  • Capacity Utilization: mid-70% range
  • 2025 CAPEX: US$1.8 billion

Recent Developments / Announcements

Jan. 14, 2025

UMC’s Flagship Fab Designated One of 189 Smart Manufacturing Lighthouses by the World Economic Forum

Feb. 10, 2025

UMC Recognized with Double ‘A’ score for Climate Change and Water Security Leadership in CDP A List for Three Consecutive Years

Feb. 14, 2025

UMC Ranks Top 1% in the Semiconductor Industry in S&P Global Sustainability Yearbook 2025

Feb. 26, 2025

UMC Board of Directors Announces Proposals for its Annual Shareholders Meeting

Apr. 01, 2025

UMC Unveils New Fab Expansion in Singapore in Grand Opening Ceremony

Please visit UMC’s website for further details regarding the above announcements

Conference Call / Webcast Announcement

Wednesday, April 23, 2025

Time:5:00 PM (Taipei) / 5:00 AM (New York) / 10:00 AM (London)

Dial-in numbers and Access Codes:

 

Taiwan Number:

02 3396 1191

Taiwan Toll Free:

0080 119 6666

US Toll Free:

+1 866 212 5567

Other Areas:

+886 2 3396 1191

 

 

Access Code:

3707023#

A live webcast and replay of the 1Q25 results announcement will be available at www.umc.com under the “Investors / Events” section.

About UMC

UMC (NYSE: UMC, TWSE: 2303) is a leading global semiconductor foundry company. The company provides high-quality IC fabrication services, focusing on logic and various specialty technologies to serve all major sectors of the electronics industry. UMC’s comprehensive IC processing technologies and manufacturing solutions include Logic/Mixed-Signal, embedded High-Voltage, embedded Non-Volatile-Memory, RFSOI, BCD etc. Most of UMC’s 12-in and 8-in fabs with its core R&D are in Taiwan, with additional ones throughout Asia. UMC has a total of 12 fabs in production with a combined capacity of more than 400,000 wafers per month (12-in equivalent), and all of them are certified with IATF 16949 automotive quality standards. UMC is headquartered in Hsinchu, Taiwan, plus local offices in the United States, Europe, China, Japan, Korea, and Singapore, with a worldwide total of 20,000 employees. For more information, please visit: http://www.umc.com.

Safe Harbor Statements

This press release contains forward-looking statements within the meaning of Section 27A of the United States Securities Act of 1933, as amended, and Section 21E of the United States Securities Exchange Act of 1934, as amended, and as defined in the United States Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, statements regarding anticipated financial results for the first quarter of 2025; the expected wafer shipment and ASP; the anticipated annual budget; capex strategies; environmental protection goals and water management strategies; impact of foreign currency exchange rates; expected foundry capacities; the ability to obtain new business opportunities; and information under the heading “Second Quarter 2025 Outlook and Guidance.”

These forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual performance, financial condition or results of operations of UMC to be materially different from what is stated or may be implied in such forward-looking statements. Investors are cautioned that actual events and results could differ materially from those statements as a result of a number of factors including, but not limited to: (i) dependence upon the frequent introduction of new services and technologies based on the latest developments in the industry in which UMC operates; (ii) the intensely competitive semiconductor, communications, consumer electronics and computer industries and markets; (iii) the risks associated with international business activities; (iv) dependence upon key personnel; (v) general economic and political conditions; (vi) possible disruptions in commercial activities caused by natural and human-induced events and disasters, including natural disasters, terrorist activity, armed conflict and highly contagious diseases; (vii) reduced end-user purchases relative to expectations and orders; and (viii) fluctuations in foreign currency exchange rates. Further information regarding these and other risk factors is included in UMC’s filings with the United States Securities and Exchange Commission, including its Annual Report on Form 20-F. All information provided in this release is as of the date of this release and are based on assumptions that UMC believes to be reasonable as of this date, and UMC does not undertake any obligation to update any forward-looking statement as a result of new information, future events or otherwise, except as required under applicable law.

The financial statements included in this release are prepared and published in accordance with Taiwan International Financial Reporting Standards, or TIFRSs, recognized by the Financial Supervisory Commission in the ROC, which is different from International Financial Reporting Standards, or IFRSs, issued by the International Accounting Standards Board. Investors are cautioned that there may be significant differences between TIFRSs and IFRSs. In addition, TIFRSs and IFRSs differ in certain significant respects from generally accepted accounting principles in the ROC and generally accepted accounting principles in the United States.

– FINANCIAL TABLES TO FOLLOW –

UNITED MICROELECTRONICS CORPORATION AND SUBSIDIARIES
Consolidated Condensed Balance Sheet
As of March 31, 2025
Figures in Millions of New Taiwan Dollars (NT$) and U.S. Dollars (US$)
 
 
March 31, 2025
US$ NT$ %
Assets
Current assets
Cash and cash equivalents

3,205

106,354

18.6

%

Accounts receivable, net

1,049

34,801

6.1

%

Inventories, net

1,068

35,425

6.2

%

Other current assets

475

15,744

2.8

%

Total current assets

5,796

192,323

33.6

%

 
Non-current assets
Funds and investments

2,152

71,407

12.5

%

Property, plant and equipment

8,501

282,051

49.2

%

Right-of-use assets

240

7,948

1.4

%

Other non-current assets

580

19,233

3.4

%

Total non-current assets

11,472

380,639

66.4

%

Total assets

17,268

572,962

100.0

%

 
Liabilities
Current liabilities
Short-term loans

196

6,500

1.1

%

Payables

1,327

44,018

7.7

%

Current portion of long-term liabilities

336

11,132

1.9

%

Other current liabilities

338

11,224

2.0

%

Total current liabilities

2,196

72,873

12.7

%

 
Non-current liabilities
Bonds payable

741

24,586

4.3

%

Long-term loans

604

20,041

3.5

%

Lease liabilities, noncurrent

172

5,700

1.0

%

Other non-current liabilities

1,776

58,933

10.3

%

Total non-current liabilities

3,293

109,260

19.1

%

Total liabilities

5,489

182,134

31.8

%

 
Equity
Equity attributable to the parent company
Capital

3,785

125,584

21.9

%

Additional paid-in capital

452

14,995

2.6

%

Retained earnings and other components of equity

7,535

250,026

43.6

%

Total equity attributable to the parent company

11,772

390,605

68.2

%

Non-controlling interests

7

224

0.0

%

Total equity

11,779

390,829

68.2

%

Total liabilities and equity

17,268

572,962

100.0

%

 
Notes:
(1) New Taiwan Dollars have been translated into U.S. Dollars at the March 31, 2025 exchange rate of NT $33.18 per U.S. Dollar.
(2) Sums may not equal totals due to rounding.

UNITED MICROELECTRONICS CORPORATION AND SUBSIDIARIES

Consolidated Condensed Statements of Comprehensive Income

Figures in Millions of New Taiwan Dollars (NT$) and U.S. Dollars (US$)

Except Per Share and Per ADS Data

 

Year over Year Comparison

Quarter over Quarter Comparison

Three-Month Period Ended

Three-Month Period Ended

March 31, 2025

March 31, 2024

Chg.

March 31, 2025

December 31, 2024

Chg.

US$ NT$ NT$ % US$ NT$ NT$ %
Operating revenues

1,744

 

57,859

 

54,632

 

5.9

%

1,744

 

57,859

 

60,386

 

(4.2

%)

Operating costs

(1,278

)

(42,412

)

(37,733

)

12.4

%

(1,278

)

(42,412

)

(42,043

)

0.9

%

Gross profit

466

 

15,447

 

16,899

 

(8.6

%)

466

 

15,447

 

18,343

 

(15.8

%)

26.7

%

26.7

%

30.9

%

26.7

%

26.7

%

30.4

%

Operating expenses
– Sales and marketing expenses

(19

)

(619

)

(684

)

(9.5

%)

(19

)

(619

)

(623

)

(0.7

%)

– General and administrative expenses

(46

)

(1,542

)

(1,702

)

(9.4

%)

(46

)

(1,542

)

(1,791

)

(13.9

%)

– Research and development expenses

(119

)

(3,964

)

(3,407

)

16.3

%

(119

)

(3,964

)

(4,334

)

(8.5

%)

– Expected credit impairment gain

0

 

2

 

46

 

(94.7

%)

0

 

2

 

0

 

523.3

%

Subtotal

(185

)

(6,123

)

(5,747

)

6.5

%

(185

)

(6,123

)

(6,748

)

(9.3

%)

Net other operating income and expenses

14

 

462

 

513

 

(9.9

%)

14

 

462

 

362

 

27.6

%

Operating income

295

 

9,786

 

11,665

 

(16.1

%)

295

 

9,786

 

11,957

 

(18.2

%)

16.9

%

16.9

%

21.4

%

16.9

%

16.9

%

19.8

%

 
Net non-operating income and expenses

(13

)

(439

)

1,056

 

 

(13

)

(439

)

(1,443

)

(69.5

%)

Income from continuing operations
before income tax

282

 

9,347

 

12,721

 

(26.5

%)

282

 

9,347

 

10,514

 

(11.1

%)

16.2

%

16.2

%

23.3

%

16.2

%

16.2

%

17.4

%

 
Income tax expense

(48

)

(1,603

)

(2,291

)

(30.0

%)

(48

)

(1,603

)

(2,054

)

(22.0

%)

Net income

233

 

7,743

 

10,430

 

(25.8

%)

233

 

7,743

 

8,460

 

(8.5

%)

13.4

%

13.4

%

19.1

%

13.4

%

13.4

%

14.0

%

 
Other comprehensive income (loss)

135

 

4,489

 

7,954

 

(43.6

%)

135

 

4,489

 

1,270

 

253.4

%

 
Total comprehensive income (loss)

369

 

12,232

 

18,384

 

(33.5

%)

369

 

12,232

 

9,730

 

25.7

%

 
Net income attributable to:
  Shareholders of the parent

234

 

7,777

 

10,456

 

(25.6

%)

234

 

7,777

 

8,497

 

(8.5

%)

  Non-controlling interests

(1

)

(34

)

(26

)

26.2

%

(1

)

(34

)

(37

)

(9.2

%)

 
Comprehensive income (loss) attributable to:
  Shareholders of the parent

370

 

12,266

 

18,410

 

(33.4

%)

370

 

12,266

 

9,767

 

25.6

%

  Non-controlling interests

(1

)

(33

)

(26

)

26.3

%

(1

)

(33

)

(37

)

(9.3

%)

 
Earnings per share-basic

0.019

 

0.62

 

0.84

 

0.019

 

0.62

 

0.68

 

Earnings per ADS (2)

0.093

 

3.10

 

4.20

 

0.093

 

3.10

 

3.40

 

Weighted average number of shares
outstanding (in millions)

12,485

 

12,414

 

12,485

 

12,481

 

 
 
Notes:
(1) New Taiwan Dollars have been translated into U.S. Dollars at the March 31, 2025 exchange rate of NT $33.18 per U.S. Dollar.
(2) 1 ADS equals 5 common shares.
(3) Sums may not equal totals due to rounding.

UNITED MICROELECTRONICS CORPORATION AND SUBSIDIARIES

Consolidated Condensed Statements of Comprehensive Income

Figures in Millions of New Taiwan Dollars (NT$) and U.S. Dollars (US$)

Except Per Share and Per ADS Data

 

For the Three-Month Period Ended

For the Three-Month Period Ended

March 31, 2025

March 31, 2025

US$

NT$

%

US$

NT$

%

Operating revenues

1,744

 

57,859

 

100.0

%

1,744

 

57,859

 

100.0

%

Operating costs

(1,278

)

(42,412

)

(73.3

%)

(1,278

)

(42,412

)

(73.3

%)

Gross profit

466

 

15,447

 

26.7

%

466

 

15,447

 

26.7

%

 
 
Operating expenses
– Sales and marketing expenses

(19

)

(619

)

(1.1

%)

(19

)

(619

)

(1.1

%)

– General and administrative expenses

(46

)

(1,542

)

(2.7

%)

(46

)

(1,542

)

(2.7

%)

– Research and development expenses

(119

)

(3,964

)

(6.9

%)

(119

)

(3,964

)

(6.9

%)

– Expected credit impairment gain

0

 

2

 

0.0

%

0

 

2

 

0.0

%

Subtotal

(185

)

(6,123

)

(10.6

%)

(185

)

(6,123

)

(10.6

%)

Net other operating income and expenses

14

 

462

 

0.8

%

14

 

462

 

0.8

%

Operating income

295

 

9,786

 

16.9

%

295

 

9,786

 

16.9

%

 
Net non-operating income and expenses

(13

)

(439

)

(0.8

%)

(13

)

(439

)

(0.8

%)

Income from continuing operations before income tax

282

 

9,347

 

16.2

%

282

 

9,347

 

16.2

%

 
 
Income tax expense

(48

)

(1,603

)

(2.8

%)

(48

)

(1,603

)

(2.8

%)

Net income

233

 

7,743

 

13.4

%

233

 

7,743

 

13.4

%

 
Other comprehensive income (loss)

135

 

4,489

 

7.8

%

135

 

4,489

 

7.8

%

 
Total comprehensive income (loss)

369

 

12,232

 

21.1

%

369

 

12,232

 

21.1

%

 
Net income attributable to:
  Shareholders of the parent

234

 

7,777

 

13.4

%

234

 

7,777

 

13.4

%

  Non-controlling interests

(1

)

(34

)

(0.1

%)

(1

)

(34

)

(0.1

%)

 
Comprehensive income (loss) attributable to:
  Shareholders of the parent

370

 

12,266

 

21.2

%

370

 

12,266

 

21.2

%

  Non-controlling interests

(1

)

(33

)

(0.1

%)

(1

)

(33

)

(0.1

%)

 
Earnings per share-basic

0.019

 

0.62

 

0.019

 

0.62

 

Earnings per ADS (2)

0.093

 

3.10

 

0.093

 

3.10

 

 
Weighted average number of shares outstanding (in millions)

12,485

 

12,485

 

 
Notes:
(1) New Taiwan Dollars have been translated into U.S. Dollars at the March 31, 2025 exchange rate of NT $33.18 per U.S. Dollar.
(2) 1 ADS equals 5 common shares.
(3) Sums may not equal totals due to rounding.
UNITED MICROELECTRONICS CORPORATION AND SUBSIDIARIES

Consolidated Condensed Statement of Cash Flows

For The Three-Month Period Ended March 31, 2025

Figures in Millions of New Taiwan Dollars (NT$) and U.S. Dollars (US$)

 

US$

NT$

Cash flows from operating activities :
Net income before tax

282

 

9,347

 

Depreciation & Amortization

426

 

14,128

 

Share of loss of associates and joint ventures

6

 

208

 

Income tax paid

(18

)

(585

)

Changes in working capital & others

22

 

728

 

Net cash provided by operating activities

718

 

23,826

 

 
Cash flows from investing activities :
Acquisition of property, plant and equipment

(427

)

(14,153

)

Acquisition of intangible assets

(10

)

(329

)

Others

120

 

3,976

 

Net cash used in investing activities

(317

)

(10,506

)

 
Cash flows from financing activities :
Decrease in short-term loans

(61

)

(2,015

)

Proceeds from long-term loans

39

 

1,300

 

Repayments of long-term loans

(371

)

(12,303

)

Others

(23

)

(758

)

Net cash used in financing activities

(415

)

(13,776

)

 
Effect of exchange rate changes on cash and cash equivalents

55

 

1,810

 

Net increase in cash and cash equivalents

41

 

1,354

 

 
Cash and cash equivalents at beginning of period

3,165

 

105,000

 

 
Cash and cash equivalents at end of period

3,205

 

106,354

 

 
Notes:
(1) New Taiwan Dollars have been translated into U.S. Dollars at the March 31, 2025 exchange rate of NT $33.18 per U.S. Dollar.
(2) Sums may not equal totals due to rounding.

1 Unless otherwise stated, all financial figures discussed in this announcement are prepared in accordance with TIFRSs recognized by Financial Supervisory Commission in the ROC, which is different from IFRSs issued by the International Accounting Standards Board. They represent comparisons among the three-month period ending March 31, 2025, the three-month period ending December 31, 2024, and the equivalent three-month period that ended March 31, 2024. For all 1Q25 results, New Taiwan Dollar (NT$) amounts have been converted into U.S. Dollars at the March 31, 2025 exchange rate of NT$ 33.18 per U.S. Dollar.

2 Revenue in this section represents wafer sales

3 Utilization Rate = Quarterly Wafer Out / Quarterly Capacity

4 Estimated capacity numbers are based on calculated maximum output rather than designed capacity. The actual capacity numbers may differ depending upon equipment delivery schedules, pace of migration to more advanced process technologies, and other factors affecting production ramp-up.

Michael Lin / David Wong

UMC, Investor Relations

+ 886-2-2658-9168, ext. 16900

[email protected]

[email protected]

KEYWORDS: Taiwan Asia Pacific

INDUSTRY KEYWORDS: Semiconductor Hardware Mobile/Wireless Technology Telecommunications

MEDIA:

Logo
Logo

Voya Financial names Trevor Ogle as its Chief Legal Officer

Voya Financial names Trevor Ogle as its Chief Legal Officer

NEW YORK–(BUSINESS WIRE)–
Voya Financial, Inc. (NYSE: VOYA) announced today that Trevor Ogle has been named the firm’s Chief Legal Officer (CLO), effective May 2, 2025.

In his expanded role, Ogle will lead Voya’s Law & Compliance department, while retaining his existing responsibility for Voya’s strategy and corporate development functions. Law & Compliance had previously been led by My Chi To, who will leave Voya on May 2 for an opportunity outside the firm.

“This role expansion recognizes Trevor’s exceptional contributions to Voya, on both the legal and business side, creating value through strategic vision and execution,” said Heather Lavallee, chief executive officer, Voya Financial. “Trevor’s legal acumen, track record of leadership within our executive team, and extensive experience with Voya’s business make him an ideal choice for this expanded role.”

Ogle has been with Voya since it became a public company in 2013. His career at the company began in Voya’s legal department, where he served as deputy general counsel responsible for corporate law. In that role, and subsequently as Voya’s Head of Corporate Development and then as its Chief Strategy and M&A Officer, Ogle has been instrumental in driving Voya’s growth and development over the past 12 years. He has been a key player in identifying and capitalizing on new opportunities, fostering strategic partnerships, and developing and executing Voya’s business strategy. Prior to joining Voya, Ogle practiced with a prominent New York-based global law firm.

“I want to thank My Chi for her tireless effort in significantly developing our law and compliance function during her tenure with Voya. I also want to congratulate Trevor. Trevor’s skills and experience will help us identify and capture new opportunities while maintaining the standards of legal excellence that our stakeholders expect,” said Lavallee.

About Voya Financial®

Voya Financial, Inc. (NYSE: VOYA) is a leading health, wealth and investment company with approximately 10,000 employees who are focused on achieving Voya’s aspirational vision: “Clearing your path to financial confidence and a more fulfilling life.” Through products, solutions and technologies, Voya helps its approximately 15.7 million individual, workplace and institutional clients become well planned, well invested and well protected. Benefitfocus, a Voya company and a leading benefits administration provider, extends the reach of Voya’s workplace benefits and savings offerings by engaging directly with approximately 11.9 million employees in the U.S. Certified as a “Great Place to Work” by the Great Place to Work® Institute, Voya is purpose-driven and committed to conducting business in a way that is economically, ethically, socially and environmentally responsible. Voya has earned recognition as one of the World’s Most Ethical Companies® by Ethisphere; a member of the Bloomberg Gender-Equality Index; and a “Best Place to Work for Disability Inclusion” on the Disability Equality Index. For more information, visit voya.com. Follow Voya Financial on Facebook, LinkedIn and Instagram.

VOYA-CF

Media Contact:

Natasha D. Smith

Voya Financial

(404) 451-9694

[email protected]

KEYWORDS: United States North America New York

INDUSTRY KEYWORDS: Finance Professional Services Legal Asset Management Insurance

MEDIA:

Logo
Logo

Lawsuit for Investors in shares of Intellia Therapeutics, Inc. (NASDAQ: NTLA) announced by the Shareholders Foundation

PR Newswire


SAN DIEGO
, April 23, 2025 /PRNewswire/ — Shareholders Foundation, Inc. announces that a lawsuit is pending for certain investors in shares of Intellia Therapeutics, Inc. (NASDAQ: NTLA).

Investors who purchased shares of Intellia Therapeutics, Inc. (NASDAQ: NTLA) prior to July 2024 and continue to hold any of those NASDAQ: NTLA shares also have certain options and contact the Shareholders Foundation at [email protected] or call +1(858) 779 – 1554.

On February 11, 2025, a NASDAQ: NTLA investor filed a lawsuit against Intellia Therapeutics, Inc. over alleged violations of securities laws. The plaintiff alleged that between July 30, 2024 and January 08, 2025, the defendants made false and/or misleading statements and/or failed to disclose that the defendants created the false impression that they possessed reliable information pertaining to the viability of NTLA-3001’s development and eventual marketing, if approved, that Intellia’s optimistic reports of timelines, including dosing and future studies of the drug, fell short of reality; the NTLA program was not viable or sustainable for Intellia because viral-based editing programs remained expensive and inefficient in comparison to then-existing non-viral delivery methods, that Intellia was not equipped to timely dose patients with NTLA-3001, maintain the drug’s research and development, or even to maintain its full staff in light of the existing scientific landscape surrounding viral-based editing drugs, and that even if NTLA-3001 proved successful, the use of viral-based editing drugs is costly, inefficient, and poor mitigators of adverse effects in patients.

Those who purchased shares of Intellia Therapeutics, Inc. (NASDAQ: NTLA) should contact the Shareholders Foundation, Inc.

CONTACT:
Shareholders Foundation, Inc.
Michael Daniels
+1 (858) 779-1554
[email protected]
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108

The Shareholders Foundation, Inc. is a professional portfolio legal monitoring and a settlement claim filing service, which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. The Shareholders Foundation, Inc. is not a law firm. Any referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is only provided as a public service. It is not intended as legal advice and should not be relied upon.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/lawsuit-for-investors-in-shares-of-intellia-therapeutics-inc-nasdaq-ntla-announced-by-the-shareholders-foundation-302435434.html

SOURCE Shareholders Foundation, Inc.

New Toll Brothers Luxury Townhome Community, Stonemill Village, is Now Open in Downingtown, Pennsylvania

DOWNINGTOWN, Pa., April 23, 2025 (GLOBE NEWSWIRE) — Toll Brothers, Inc. (NYSE:TOL), the nation’s leading builder of luxury homes, today announced its newest Chester County townhome community, Stonemill Village, is now open for sale. The Toll Brothers Sales Center and model home are open for tours at 5 Grayson Lane in Downingtown, Pennsylvania.

Located in the prestigious Downingtown Area School District, Stonemill Village will feature 89 two-story townhomes in a quiet neighborhood close to every convenience. Home shoppers will be able to choose from a variety of exquisite home designs ranging from 1,825 to 2,114+ square feet, with 3 bedrooms, 2 to 3.5 baths, and 1- to 2-car garages, each built with the outstanding quality, craftsmanship, and value for which Toll Brothers is known. Onsite amenities include walking trails throughout the community, a tot lot, and an outdoor fitness station. The community offers residents a low-maintenance lifestyle with lawn care, snow removal, trash, and recycling included.

Stonemill Village offers an array of quick move-in homes available for delivery as early as July and August 2025 – just in time for the new school year. Toll Brothers quick move-in homes with Designer Appointed Features include a curated ensemble of fixtures and finishes selected by award-winning design professionals. In addition, a select number of build-to-order homes will also be available for Toll Brothers customers to personalize their selections at the Toll Brothers Design Studio.

“We are excited to offer our signature build-to-order homes as well as beautiful quick move-in homes at Stonemill Village that are available for every timeline,” said John Dean, Division President of Toll Brothers in Pennsylvania. “With floor plans designed with home offices, basements on select home sites, and outstanding personalization options, Stonemill Village will offer residents the best in luxury living in a tranquil location close to everything.” 

Toll Brothers residents will enjoy proximity to nearby shopping, dining, arts and entertainment, and recreational destinations, including Marsh Creek State Park, Eagle Village Shops, Main Street at Exton, King of Prussia Mall and Town Center at King of Prussia, as well as Philadelphia’s sporting arenas, stadiums, and more.   

Major highways including Routes 202 and 30 and the Pennsylvania Turnpike are easily accessible from Stonemill Village, offering homeowners convenient access to Philadelphia, New Jersey beaches, Pocono Mountains, and New York City.  

Additional Toll Brothers new home communities in the Chester County area include Anfield at Malvern, Preserve at Marsh Creek – Carriage Collection, and Riverstone Crossing.

Homes in Stonemill Village are priced from the mid-$500,000s. For more information on this Toll Brothers luxury townhome new construction community, home shoppers are invited to call (855) 872-8205 or visit TollBrothers.com/Pennsylvania.

About Toll Brothers 
Toll Brothers, Inc., a Fortune 500 Company, is the nation’s leading builder of luxury homes. The Company was founded 58 years ago in 1967 and became a public company in 1986. Its common stock is listed on the New York Stock Exchange under the symbol “TOL.” The Company serves first-time, move-up, empty-nester, active-adult, and second-home buyers, as well as urban and suburban renters. Toll Brothers builds in over 60 markets in 24 states: Arizona, California, Colorado, Connecticut, Delaware, Florida, Georgia, Idaho, Indiana, Maryland, Massachusetts, Michigan, Nevada, New Jersey, New York, North Carolina, Oregon, Pennsylvania, South Carolina, Tennessee, Texas, Utah, Virginia, and Washington, as well as in the District of Columbia. The Company operates its own architectural, engineering, mortgage, title, land development, smart home technology, and landscape subsidiaries. The Company also develops master-planned and golf course communities as well as operates its own lumber distribution, house component assembly, and manufacturing operations.    

Toll Brothers has been one of Fortune magazine’s World’s Most Admired Companies™ for 10+ years in a row, and in 2024 the Company’s Chairman and CEO Douglas C. Yearley, Jr. was named one of 25 Top CEOs by Barron’s magazine. Toll Brothers has also been named Builder of the Year by Builder magazine and is the first two-time recipient of Builder of the Year from Professional Builder magazine. For more information visit TollBrothers.com.

From Fortune, ©2025 Fortune Media IP Limited. All rights reserved. Used under license.

Contact: Andrea Meck | Toll Brothers, Senior Director, Public Relations & Social Media | 215-938-8169 | [email protected]

Photos accompanying this announcement are available at: 

https://www.globenewswire.com/NewsRoom/AttachmentNg/3ae21ddc-7776-4922-896c-3211f5c02296

https://www.globenewswire.com/NewsRoom/AttachmentNg/a5dee81d-db4e-4937-9bbd-beb66850c2b4

Sent by Toll Brothers via Regional Globe Newswire (TOLL-REG)



Beaver Hollow Wellness Responds to Servotronics’ Escalating Proxy Tactics

PR Newswire

Calls for Accountability and Shareholder-Centered Reform


BUFFALO, N.Y.
, April 23, 2025 /PRNewswire/ — Beaver Hollow Wellness, LLC (“BHW”), the largest active shareholder of Servotronics, Inc. (NASDAQ: SVT), today issued the following statement in response to the Company’s amended proxy statement filed April 22, 2025:

“Servotronics’ latest filing is a clear sign of a board under pressure and out of touch,” said Paul L. Snyder III, Chairman of BHW. “The escalation in rhetoric, along with newly inserted language about ‘change of control’ compensation, demonstrates that the Company is more focused on protecting executive payouts than delivering value to shareholders.”

Change of Control Provisions – A Self-Serving Shield
In a newly inserted clause, the Board claims that replacing a majority of directors could trigger “change in control” provisions that result in accelerated equity awards and enhanced severance benefits for current executives. It is outrageous that the very Board responsible for awarding these outlandish payouts, is now attempting to use them as a scare tactic with shareholders.

This Board has focused on granting Golden Parachutes to their cronies, in stark contrast BHW is focused on rebuilding this once great manufacturing company. Any executive payout should be fair, transparent, and performance-based—not triggered by shareholder votes for accountability.

BHW Reaffirms Its Commitment to Responsible Stewardship
BHW seeks to implement lean manufacturing principles, overhaul supply chain operations, and ensure zero-defect deliverability. not to disrupt the company’s operations. Instead, it seeks to introduce oversight that prioritizes shareholder interests, responsible capital allocation, and operational excellence. The nominees include professionals with backgrounds in aerospace, finance, manufacturing, and governance.

“We call on shareholders to reject the fear tactics and vote for experience, independence, and accountability,” Snyder said. “Our SAVE Servotronics plan is clear, constructive, and credible.”

Vote for Real Change
BHW urges shareholders to use the WHITE universal proxy card to vote for all four BHW nominees:
Paul L. Snyder III
Christine R. Marlow
Michael W. Dolpp
Charles C. Alfiero

For more information, visit: www.SaveServotronics.com

Media Contact

Kevin Keenan

Keenan Communications Group
(716) 481-6806
[email protected]

Investor Contact

Brian Valerio

Alliance Advisors
[email protected]

Cision View original content:https://www.prnewswire.com/news-releases/beaver-hollow-wellness-responds-to-servotronics-escalating-proxy-tactics-302435938.html

SOURCE Beaver Hollow Wellness

/C O R R E C T I O N from Source — BRP Inc./

PR Newswire

In the news release, BRP Announces Annual and Special Meeting of Shareholders will be Held on May 29, 2025, issued 23-Apr-2025 by BRP Inc. over CNW, we are advised by the company that the first paragraph should read “Thursday, May 29, 2025” rather than “Friday, May 29, 2025” as originally issued inadvertently. The complete, corrected release follows:

BRP Announces Annual and Special Meeting of Shareholders will be Held on May 29, 2025


VALCOURT, QC
, April 23, 2025 /PRNewswire/ – BRP Inc. (TSX: DOO) (NASDAQ: DOOO) (“BRP” or the “Company“) announces that its annual and special meeting of shareholders (the “Meeting“) will be held on Thursday, May 29, 2025 at 11:00 a.m. EDT and will be conducted by live webcast.

The Company is holding the Meeting as a completely virtual meeting, which all shareholders, regardless of geographic location and equity ownership, will have an equal opportunity to attend.  Registered shareholders and duly appointed proxy holders are strongly encouraged to vote their shares in advance of the Meeting as described in the Company’s Management Information Circular posted concurrently herewith on brp.com, on SEDAR+ and on EDGAR, or to vote virtually at the Meeting online. Voting results for each of the resolutions will be announced after the Meeting and reported on SEDAR+.

Shareholders who wish to participate online can go to https://meetings.lumiconnect.com/400-202-255-442 and click “I have a login” and then enter the 15-digit control number located on their form of proxy and the password “brp2025”. Anyone can join the Meeting as a guest by clicking on “Guest” and completing the online form. Guests will be able to listen to the Meeting but will not be able to vote or ask questions. Shareholders and guests may also attend the Meeting by conference call at the following numbers:

  • French: 1-877-859-1484
  • English: 1-888-977-5948
  • Original (without interpretation): 1-888-870-3025

Following the Meeting, the webcast of the Meeting will be accessible on the Company’s website at brp.com until next year’s annual meeting of shareholders.

Registered shareholders and duly appointed proxy holders will also be entitled to submit questions to the Company in advance of the Meeting by email at [email protected], and during the Meeting through the platform available at https://meetings.lumiconnect.com/400-202-255-442, which questions will, subject to certain verifications by the Company, be addressed at the Meeting. Questions sent in advance by e-mail must be provided by no later than 11:00 a.m. (EDT) on May 27, 2025, or if the Meeting is postponed or adjourned, by no later than 48 hours prior to the time of such postponed or adjourned meeting (excluding Saturdays, Sundays and holidays).

About BRP

BRP Inc. is a global leader in the world of powersports products, propulsion systems and boats built on over 80 years of ingenuity and intensive consumer focus. Through its portfolio of industry-leading and distinctive brands featuring Ski-Doo and Lynx snowmobiles, Sea-Doo watercraft and pontoons, Can-Am on and off-road vehicles, Alumacraft and Quintrex boats, Manitou pontoons and Rotax marine propulsion systems as well as Rotax engines for karts and recreational aircraft, BRP unlocks exhilarating adventures and provides access to experiences across different playgrounds. The Company completes its lines of products with a dedicated parts, accessories and apparel portfolio to fully optimize the riding experience. Committed to growing responsibly, BRP is developing electric models for its existing product lines. Headquartered in Quebec, Canada, BRP had annual sales of CA$7.8 billion from over 130 countries and employed approximately 16,500 driven, resourceful people as of January 31, 2025.


www.brp.com



@BRPNews

Ski-Doo, Lynx, Sea-Doo, Can-Am, Rotax, Alumacraft, Manitou, Quintrex, and the BRP logo are trademarks of Bombardier Recreational Products Inc. or its affiliates. All other trademarks are the property of their respective owners.

Caution concerning forward-looking statements

Certain statements included in this press release constitute “forward-looking statements” within the meaning of applicable securities laws. The words “may”, “will”, “would”, “should”, “could”, “expects”, “forecasts”, “plans”, “intends”, “trends”, “indications”, “anticipates”, “believes” “estimates”, “outlook”, “predicts”, “projects”, “likely” or “potential” or the negative or other variations of these words or other comparable words or phrases, are intended to identify forward-looking statements. Forward-looking statements, by their nature, involve inherent risks and uncertainties and are based on a number of assumptions, and are subject to important risks and uncertainties, both general and specific, made by the Company in light of its experience and perception of historical trends. Forward-looking statements cannot be relied upon due to, amongst other things, changing external events and general uncertainties of the business. Forward-looking statements are subject to numerous factors, many of which are beyond BRP’s control, including the risk factors disclosed previously and from time to time in BRP’s filings with the securities regulatory authorities in each of the provinces and territories of Canada and the United States, available on SEDAR+ at sedarplus.com or EDGAR at sec.gov, respectively. The forward-looking statements contained in this press release are made as of the date of the press release (or as of the date they are otherwise stated to be made), and are subject to change after such date and the Company has no intention and undertakes no obligation to update or revise any forward-looking statements to reflect future events, changes in circumstances, or changes in beliefs, unless required by applicable securities regulations.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/brp-announces-annual-and-special-meeting-of-shareholders-will-be-held-on-may-29-2025-302435937.html

SOURCE BRP Inc.

LakeShore Biopharma Announces the Official Launch of a Novel Packaging Solution for YSJA™ Rabies Vaccine (Vero Cell)

PR Newswire

Revolutionizing Vaccination Safety with Needle-Free Reconstitution Technology


BEIJING
, April 23, 2025 /PRNewswire/ — On April 18, 2025, LakeShore Biopharma Co., Ltd. (Nasdaq: LSB) (“LakeShore Biopharma” or the “Company”) successfully held the 2025 CSO (“Contract Sales Organization”) Annual Meeting and the launch meeting of YSJA™ rabies vaccine (Vero cell) novel packaging solution (liquid drug transfer device) in Changsha, Hunan Province. Approved for lot release by regulatory authorities on April 15, 2025, the new formulation will begin nationwide distribution in China within weeks, addressing critical safety challenges in vaccine administration.

To address pain points such as compounding contamination, occupational exposure of medical staff and needle tip pain, the novel packaging YSJA™ vaccine has been upgraded accordingly. In addition, the novel packaging product is equipped with specially designed clasp, puncture device and suction head, which can realize automatic clamping, needle-free reconstitution and new needle injection, improve the convenience and safety of vaccination, reduce the risk of particle pollution and inflammation, and protect medical staff from needlestick injuries. The new packaging product of YSJA™ rabies vaccine has filled the gap in the Chinese market, and its innovative design was highly recognized by the CSOs participating in the conference.

“The YSJA™ packaging innovation represents humanized design in vaccine delivery,” stated Mr. Wang Xu, CEO of LakeShore Biopharma. “By leveraging closed sterile connection technology, this novel design will gradually address the industry pain points of “occupational exposure and pollution risk” in the traditional liquid preparation process. This launch marks the first commercial application of such advanced liquid transfer device in China’s rabies vaccine market, filling a significant unmet need.” With rabies remaining a critical public health threat in endemic regions, the company will continue to be committed to empowering medical safety with science and technology in the future.

For media inquiries, please contact:
Website: https://investors.lakeshorebio.com/
Email: [email protected] 

Cision View original content:https://www.prnewswire.com/news-releases/lakeshore-biopharma-announces-the-official-launch-of-a-novel-packaging-solution-for-ysja-rabies-vaccine-vero-cell-302435932.html

SOURCE LakeShore Biopharma Co., Ltd.